Aribio Lab on the cusp of a change in its largest shareholder, unveils plan to develop an Alzheimer's disease (AD) prevention vaccine

[Financial News] Aribio Lab announced on the 10th that it would unveil for the first time its plan to develop an AD prevention vaccine, ahead of a change in its largest shareholder. With Aribio Co., Ltd., a developer of AD treatments, set to replace current largest shareholder ARIBIO Holdings, Aribio Lab presented a dementia prevention vaccine as a new business area.
The announcement comes four days before Aribio Co., Ltd. releases the global Phase 3 results for its oral AD treatment, AR1001. After the two companies decided to invest in each other and pursue AD treatment and prevention, respectively, attention is focused on whether this will lead to joint research and development and business cooperation in the future.
Aribio Lab will attend the Korean Society for Immunology International Congress (KAI 2026), to be held from the 12th to the 14th at Songdo Convensia in Incheon, where it will unveil for the first time its plans for new pipelines in prevention vaccines for AD and other degenerative brain diseases, as well as in anti-aging.
Last September, Aribio Co., Ltd. decided to invest 15 billion won in Aribio Lab's 18-billion-won paid-in capital increase through a third-party allotment. Once payment for the increase is completed, Aribio Co., Ltd. will replace ARIBIO Holdings as Aribio Lab's largest shareholder.
This is expected to create a structure in which Aribio Co., Ltd. directly controls Aribio Lab, bringing changes to the two companies' research and development and commercialization strategies as well. Some observers are also watching for the possibility that this restructuring could lead to a merger between the two companies in the future.
Mutual investment between the two companies is also expanding. At a board meeting on the 4th, Aribio Lab decided to acquire for 10 billion won bonds with a face value of 5 billion won from the 26th convertible bond (CB) issuance by Aribio Co., Ltd.
An industry official said, “Combining disease research experience gained through treatment trials with vaccine platform technology can broaden the scope of research into prevention,” and predicted, “The specifics of actual cooperation will depend on how the two companies set out the targets for their prevention vaccines and their plans for initial validation.”
Aribio Co., Ltd. has completed the global Phase 3 trial of AR1001, involving 1,535 patients in 13 countries, and plans to announce key results at CTAD 2026, which will be held in Boston, United States, on the 16th. Before then, Aribio Lab plans to present its concept for an AD prevention vaccine, extending the group's brain disease research and development capabilities into prevention.
Aribio Lab's key competitive strength is its proprietary immune-enhancing technology, which boosts vaccine efficacy. Its self-developed Lipo-pamTM is the only product from a Korean company listed in the vaccine adjuvant library of the Coalition for Epidemic Preparedness Innovations (CEPI). The company is pursuing various commercialization opportunities based on the technology, including joint development with global vaccine developers, supply of adjuvants and technology transfers. It has also partnered with Samjin Pharmaceutical on joint vaccine development and commercialization.
The existing vaccine pipeline is also approaching key clinical milestones. The shingles prevention vaccine CVI-VZV-001, the most advanced candidate in development, demonstrated safety and a 100% seroprotection rate in Phase 1, and dosing in Phase 2 has now been completed. The company plans to announce Phase 2 results in the first quarter of 2027 and proceed with subsequent clinical development.
Jaejun Jeong, CEO of Aribio Lab, said, “Aribio Co., Ltd.'s capabilities in developing AD treatments and Aribio Lab's proprietary immune-enhancing platform are complementary strengths built up in different fields.” He added, “Based on the technologies and research and development capabilities held by the two companies, we will keep all possibilities open and do our utmost to maximize shareholder value.”

[email protected] Choi Doo-seon Reporter